Wednesday, November 24, 2021 3:00:19 AM
I just finished doing this complex chart for myself.
I'll share it with you.
Looking at the true top 21.30
Yes,I think 20 and 21 is possible but I also think this could be the highest target for this current pattern.
Step by step,climbing back up the same target steps, first 18.40 area, like the previous rally did (the one from 16.69 Bottom)
Major magnetic target zone I want to watch is 18.80-19.00 and then 19.30.
then 19.80 area. These are the Fib retrace targets in both directions. This extreme plunge to 17.39 was way overblown in one fell swoop. and now we get to watch how the reaction goes. in a shortened week as well.
20 dollars is one of the Fib targets in this picture. but it will take some climbing thru key resistance that will need close watching.It could get capped around 19.00-19.30 area
--------------------------------------------------
But to avoid confusion and hostility,I want to add ... that I am not making a prediction...I made a road map to examine. a track pattern to watch , and see IF it plays out, to see IF the price runs along these tracks, in an Elliott Wave pattern, to Fibonacci targets. Thats all it is, a method of analysis. When the price climbs,I will watch where it stalls out. where it hits resistance and where it finds support, along the way, to Target areas. IF the day follows the track pattern I am anticipating, thats a good day for a chart architect. or a bus driver. It's not a prediction. It's a set of train tracks to watch.
I'll share it with you.
Looking at the true top 21.30
Yes,I think 20 and 21 is possible but I also think this could be the highest target for this current pattern.
Step by step,climbing back up the same target steps, first 18.40 area, like the previous rally did (the one from 16.69 Bottom)
Major magnetic target zone I want to watch is 18.80-19.00 and then 19.30.
then 19.80 area. These are the Fib retrace targets in both directions. This extreme plunge to 17.39 was way overblown in one fell swoop. and now we get to watch how the reaction goes. in a shortened week as well.
20 dollars is one of the Fib targets in this picture. but it will take some climbing thru key resistance that will need close watching.It could get capped around 19.00-19.30 area
--------------------------------------------------
But to avoid confusion and hostility,I want to add ... that I am not making a prediction...I made a road map to examine. a track pattern to watch , and see IF it plays out, to see IF the price runs along these tracks, in an Elliott Wave pattern, to Fibonacci targets. Thats all it is, a method of analysis. When the price climbs,I will watch where it stalls out. where it hits resistance and where it finds support, along the way, to Target areas. IF the day follows the track pattern I am anticipating, thats a good day for a chart architect. or a bus driver. It's not a prediction. It's a set of train tracks to watch.
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
